Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)

Phase 3

Completed

• Conditions: Multiple Myeloma
• Interventions: Drug: Thalidomide®; Drug: Cyclophosphamide; Drug: Velcade®; Drug: Dexaméthasone

• Registration Number: NCT01971658
• Lead Sponsor: Nantes University Hospital

Brief Summary

This is a phase III, multicenter, prospective with a clinical benefit, open-label and randomized study to compare two different treatments : Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) versus Velcade (Bortezomib) Cyclophosphamide Dexamethasone (VCD) as an Induction Treatment prior to Autologous Stem Cell Transplantation in patients with Newly Diagnosed Multiple Myeloma.

Eligible patients will be randomized into 2 treatment arms. Each patient will receive 4 consecutive 21 day cycles of an induction treatment with either VTD or VCD.

Detailed Description

The patient population will consist of adult men and women who have a confirmed diagnosis of Multiple Myeloma and who meet eligibility criteria. They will be recruited from among the patients consulting in an investigating centre's haematology service for newly diagnosed, symptomatic, untreated multiple myeloma.

in each treatment arm there will be :

1. Induction therapy : 4 cycles of VTD (21 days)or VCD

2. Systematic stem cell harvest after cycle 3

Study Timeline

• Study First Submitted: 2013-09-30
• Study Start: 2013-10
• Study First Submitted QC: 2013-10-23
• Study First Posted: 2013-10-29
• Primary Completion: 2015-08
• Study Completion: 2015-08
• Status Verified: 2015-10
• Last Update Submitted: 2015-10-06
• Last Update Posted: 2015-10-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 358

Inclusion Criteria

Patients newly diagnosed with symptomatic Multiple Myeloma (MM) patient

1. • 18 ≤ age < 66 years
2. • Eastern Cooperative Oncology Group Performance Status of 0, 1 or 2
3. • Patients must be eligible for Autologous Stem Cell Transplantation
4. • Patients must have measurable disease by serum M-protein ≥ 10 g/L and/or urine M-protein ≥200mg/day
5. • Female patients of child-bearing potential (FCBP):
   • Must agree to have medically supervised pregnancy tests prior to starting study and every 21 days, including 4 weeks after the end of study treatment. This applies even if the patient practices complete and continued sexual abstinence.
   • Must agree to use and be able to comply with effective contraception without interruption, 28 days prior to starting study drug, during the study therapy (including during periods of dose interruptions), and for 28 days after discontinuation of study therapy.
6. • Male Patients:
   • Must agree to use a condom during sexual contact with a FCBP, throughout study drug therapy, during any dose interruption and for one week after discontinuation of study therapy
   • Must agree to not donate semen during study drug therapy and for one week after discontinuation of study therapy
7. • All patients must:
   • Agree to abstain from donating blood while taking study drug therapy and for one week after discontinuation of study drug therapy
   • Agree not to share study medication with another person.
8. • Patients must be capable of giving informed consent
9. • Patients must be affiliated with French social security system

Exclusion Criteria

1. • Asymptomatic Multiple myeloma
2. • Non-secretory Multiple myeloma
3. • Proven AL-amyloidosis
4. • Age ≥ 66 years old
5. • Prior or current systemic therapy for Multiple myeloma, including steroids (except for emergency use of a 4-day block of dexamethasone before randomization, maximum total dose allowed 160 mg)
6. • Radiation therapy in the 2 weeks preceding randomization
7. • National Cancer Institute grade ≥ 2 peripheral neuropathy
8. • Haemoglobin < 8g/dL
9. • Absolute neutrophil count < 1,000 cells / µL, platelet count < 50,000 cells / µL
10. • Creatinine level > 170 µmol/L or requiring dialysis.
11. • Bilirubin, transaminases or GamaGT > 3 UNL (upper normal limit)
12. • Positive HIV serology, evidence of active Hepatitis B and C infection
13. • Severe active infection
14. • Inability to comply with an anti-thrombotic treatment regimen
15. • A personal medical history of severe psychiatric disease
16. • Uncontrolled diabetes contraindicating the use of high-dose dexamethasone
17. • Non-controlled or severe cardiovascular disease (including a myocardial infarction in the 6 months prior to recruitment)
18. • A personal medical history of cancer unless the patient has been without relapse after treatment discontinuation > or = 5 years (except for basocellular skin cancer or in situ cervical cancer)
19. • Use of any investigational drug in the 30 days preceding randomization

22 - Pregnant or lactating women. 23 - Adults under juridical protection 24 - Known or suspected hypersensitivity to any of the study therapies or excipients 25 - Necessity of vaccination for yellow fever or with any other live vaccines

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD)	Thalidomide®	Arm A: 1. Induction therapy 4 cycles of VTD (21 days) Thalidomide® 100 mg/day Per Os Day1 to Day21 Velcade® 1.3 mg/m²/day Subcutaneous Day1, 4, 8 and 11 Dexamethasone 40 mg/day Per Os Day 1 to 4 and Day 9 to 12 2. Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and one week after the last dose of Thalidomide, stem cells have to be harvested
VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD)	Velcade®	Arm A: 1. Induction therapy 4 cycles of VTD (21 days) Thalidomide® 100 mg/day Per Os Day1 to Day21 Velcade® 1.3 mg/m²/day Subcutaneous Day1, 4, 8 and 11 Dexamethasone 40 mg/day Per Os Day 1 to 4 and Day 9 to 12 2. Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and one week after the last dose of Thalidomide, stem cells have to be harvested
VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD)	Velcade®	For arm B: 1. Induction therapy : 4 cycles of VCD (21 days) * Cyclophosphamide 500 mg/m²/day, Per Os Day 1, 8, 15 * Velcade® and Dexamethasone identical treatment to Arm A 2. Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and two weeks after the last dose of Cyclophosphamide, stem cells have to be harvested
VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD)	Cyclophosphamide	For arm B: 1. Induction therapy : 4 cycles of VCD (21 days) * Cyclophosphamide 500 mg/m²/day, Per Os Day 1, 8, 15 * Velcade® and Dexamethasone identical treatment to Arm A 2. Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and two weeks after the last dose of Cyclophosphamide, stem cells have to be harvested
VELCADE (BORTEZOMIB) THALIDOMIDE DEXAMETHASONE (VTD)	Dexaméthasone	Arm A: 1. Induction therapy 4 cycles of VTD (21 days) Thalidomide® 100 mg/day Per Os Day1 to Day21 Velcade® 1.3 mg/m²/day Subcutaneous Day1, 4, 8 and 11 Dexamethasone 40 mg/day Per Os Day 1 to 4 and Day 9 to 12 2. Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and one week after the last dose of Thalidomide, stem cells have to be harvested
VELCADE (BORTEZOMIB) CYCLOPHOSPHAMIDE DEXAMETHASONE (VCD)	Dexaméthasone	For arm B: 1. Induction therapy : 4 cycles of VCD (21 days) * Cyclophosphamide 500 mg/m²/day, Per Os Day 1, 8, 15 * Velcade® and Dexamethasone identical treatment to Arm A 2. Systematic stem cell harvest after cycle 3 Mobilization: Cyclophosphamide and two weeks after the last dose of Cyclophosphamide, stem cells have to be harvested

Primary Outcome Measures

Name	Time	Method
Response assessment according to the criteria IMWG	15-17 month	compare the Response assessment in both arms: the Very good partial remission rate (according to the criteria IMWG) achieved with four courses of VTD with that achieved with four courses of VCD

Secondary Outcome Measures

Name	Time	Method
Response assessment according to the criteria IMWG	15-17 month	compare the Response assessment in both arms: Compare the following parameters after induction treatment with four courses of VTD or four courses of VCD the Partial remission rate (according to the criteria IMWG)
Number of Adverse Events	15-17 month	To evaluate the Safety of induction therapy
Number of collected stem cell	17 month
Number of death	17 month	To evaluate Overall and Progression-Free Survival
Number of relapse according to the criteria IMWG	17 month	Progression-Free Survival

Trial Locations

Locations (62)

Centre Hospitalier de la région d'Annecy; 🇫🇷 Annecy, Pringy, France

CHRU Hôpital Sud; 🇫🇷 Amiens, France

CHU Angers; 🇫🇷 Angers, France

Centre Hospitalier Argenteuil; 🇫🇷 Argenteuil, France

Centre Hospitalier H.Duffaut; 🇫🇷 Avignon, France

Centre Hospitalier de la Côte Basque; 🇫🇷 Bayonne, France

CHRU de Besançon; 🇫🇷 Besançon, France

Hôpital Avicenne; 🇫🇷 Bobigny, France

Polyclinique Bordeaux Nord Aquitaine; 🇫🇷 Bordeaux, France

Centre hospitalier Pierre Oudot; 🇫🇷 Bourgoin Jallieu, France

Scroll for more (52 remaining)